Acute Myelogeneous Leukemia (M5a) that Demonstrated Chromosomal Abnormality of Robertsonian 13 ; 21 Translocation at Onset
スポンサーリンク
概要
- 論文の詳細を見る
A 27-year-old woman had congenital lissencephaly syndrome and mental retardation. She had a fever of unknown origin and visited her local physician. Blood test indicated leukocytosis, so she was referred to our hospital for detailed examination. She was diagnosed to have acute myelogeneous leukemia (M5a). The chromosome analysis in blast cells revealed Robertsonian 13;21 translocation. Complete remission was obtained by induction chemotherapy. As normal karyotype (46, XX) was observed in the chromosome analysis of bone marrow cells after remission, it was considered that the patient had acquired Robertsonian 13;21 translocation complicated by acute myelogeneous leukemia.
- 社団法人 日本内科学会の論文
- 2004-06-01
著者
-
Takeyama Hideo
The Department Of Internal Medicine Nagoya Ekisaikai Hopital
-
Takeyama Hideo
The Department Of Internal Medicine Nagoya Ekisaikai Hospital
-
Kojima Yumi
The Department Of Internal Medicine Nagoya Ekisaikai Hospital
-
SHIMOKAWA Takayoshi
the Department of Internal Medicine, Nagoya Ekisaikai Hospital
-
SAKAI Mayuko
the Department of Internal Medicine, Nagoya Ekisaikai Hospital
-
Shimokawa Takayoshi
The Department Of Internal Medicine Nagoya Ekisaikai Hospital
-
Sakai Mayuko
The Department Of Internal Medicine Nagoya Ekisaikai Hospital
関連論文
- Superior Efficacy of MMCP Regimen Compared with VMCP and MMPP Regimens in the Treatment of Multiple Myeloma
- Posttreatment Nadir M-Protein Level Is a Stronger Discriminator of Survival Following Plateau Attainment Than Is Percent Reduction in M-Protein in Patients With IgG Myeloma
- Posttreatment M-Protein Nadir Level Is a Significant Prognostic Factor Associated with Survival in Multiple Myeloma
- Acute myeloid leukemia in the elderly : 159 Nagoya case studies
- Acute Myelogeneous Leukemia (M5a) that Demonstrated Chromosomal Abnormality of Robertsonian 13 ; 21 Translocation at Onset
- Superior Efficacy of MMCP Regimen Compared with VMCP and MMPP Regimens in the Treatment of Multiple Myeloma